Browse studies

Find your next paid study

180 recruiting studies matching your filters

Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction

The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or…

Colorectal CancerEndometrial CancerHereditary Cancer Syndromes

Estimated

~$10 – $750

Actual pay is set by the research site.

Weill Medical College of Cornell UniversityNCT06096688

Phase 3

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor rece…

Endometrial Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BioNTech SENCT06340568

Clinical Evidence Generation of AI Enabled Fast, Accurate and Precise Screening and Staging of Benign vs Malignant Pelvic Abnormalities

This study evaluates whether newly developed non-FDA approved image processing techniques \[Adaptive Image Reconstruction (AIR Recon) Deep Learning (DL) and So…

Endometrial CarcinomaProstate Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT07407959

Phase 2

A Phase II, Randomization, Unblinded Study of ELacestrant in Combination With Abemaciclib or Elacestrant Alone In p53 Wild Type, Estrogen Receptor-positive Advanced or recurrenT Endometrial Cancer (ELITE)

The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people wit…

Endometrial Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07209449

Phase 1

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both c…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT04590326

Observational

Health Engagement for Rural Ohio Cancer Survivors (HERO-C)

This clinical trial identifies the needs and preferences of rural stage I-III postmenopausal breast and endometrial cancer survivors and evaluates the impact o…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer CenterNCT07723235

Observational

Randomized Phase 3 Study of SELECTIVE SURGICAL STAGING Versus REFLEX Lymphadenectomy in Non-mappers Undergoing Sentinel Lymph Node Sampling for the Treatment of Endometrial Cancer

This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. T…

Endometrial Cancer

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Rachel MillerNCT06677112

Phase 1

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and to…

Non-Small Cell Lung CancerColorectal CancerBreast Cancer+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Fate TherapeuticsNCT07216105

Phase 1

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Endometrial CancerCervical CancerOvarian Cancer+7 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

SystImmune Inc.NCT06293898

Observational

A Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity-Modulated Radiation Therapy for Post-Operative Treatment of Endometrial or Cervical Cancers

This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after su…

Cervical CarcinomaEndometrial CarcinomaEndometriosis+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT04567771

Phase 3

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are consid…

Endometrial CancerRecurrent or Progressive Endometrial Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

GenmabNCT07166094

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.

Endometrial Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT06365905